HMGB1 promotes radiotherapy resistance in human cervical cancer HeLa cells through regulating the AMPK/mTOR signaling Authors: Youyou Xie, Changhui Yu, Miao Wang, Yaqin Lin, Biyun Wang Published: 2026 ABSTRACT AbstractCervical cancer (CC) ranks as the third most common malignancy among women worldwide. Radiotherapy (RT) resistance represents a major cause of clinical treatment failure and disease progression. High-mobility group box-1 (HMGB1), a nuclear protein released during RT, has been implicated in the regulation of radiation resistance. This study aimed to establish HeLa RT-resistant (HeLa-R) cells and investigate the effect of HMGB1 on RT resistance and its underlying molecular pathway. HeLa-R cells were established through fractionated X-ray irradiation. Cell viability, proliferation, migration, and invasion were assessed using methyl thiazolyl tetrazolium (MTT), colony formation, Transwell migration, and invasion assays, respectively. HMGB1 expression was analyzed by quantitative RT-PCR, Western blot, and immunofluorescence. A phospho-kinase array was performed to evaluate phosphorylation levels of key kinase sites. Following fractionated X-ray irradiation, we successfully established HeLa-R cells, which exhibited significantly elevated HMGB1 expression compared to parental cells. HMGB1 knockdown suppressed RT resistance in HeLa-R cells, accompanied by increased phosphorylation of AMP-activated protein kinase (p-AMPK). Conversely, AMPK inhibition restored cell viability, colony formation, migration, and invasion in HMGB1-deficient HeLa-R cells. Mechanistically, in HeLa-R cells, mTOR was identified as a downstream effector of AMPK signaling. Separately, clinical analysis revealed that HMGB1 levels were significantly elevated, while p-AMPK levels were markedly reduced in tumor tissues from radioresistant patients compared with radiosensitive patients. In conclusion, our in vitro findings demonstrate that HMGB1 inhibition suppresses RT resistance in HeLa-R cells through activation of the AMPK/mTOR pathway. The clinical correlations between HMGB1, p-AMPK, and radiotherapy response support the potential relevance of this pathway, although further validation in patient tissues is required.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12957-026-04461-w.Keywords: Cervical cancer, Radiotherapy resistance, HMGB1, AMPK/mTOR Introduction Cervical cancer (CC) is a malignant solid tumor originating from the epithelia of the uterine cervix [1]. Although effective screening and vaccination against cancer-causing human papillomavirus (HPV) are currently available, metastasis frequently occurs at advanced stages and remains the primary cause of high mortality among CC patients [1]. Current management of CC employs a multidisciplinary approach encompassing surgery, chemotherapy, radiotherapy (RT), and targeted therapy, with RT serving as a critical treatment modality [2, 3]. RT functions by inducing DNA damage in cancer cells, thereby eliminating tumors or alleviating disease burden. However, the efficacy of RT is frequently compromised by intrinsic or acquired radioresistance of tumor cells, leading to incomplete clearance, local recurrence, metastasis, and ultimately reduced patient survival [4]. The mechanisms underlying RT resistance are complex and multifactorial, involving cell cycle arrest, genetic alterations, tumor microenvironment remodeling, autophagy dysregulation, and the presence of cancer stem cells [4–6]. Therefore, identifying key molecular regulators of radioresistance and elucidating their associated pathways may facilitate the development of novel therapeutic strategies for CC. Tumorigenesis is a multi-step, multi-stage biological process governed by numerous genes [7]. High mobility group box protein 1 (HMGB1), a highly conserved non-histone chromatin-binding protein, predominantly localizes to the nucleus under physiological conditions [8–10]. In response to various stimuli, HMGB1 undergoes nuclear-cytoplasmic translocation and participates in regulating gene transcription, cell differentiation, and DNA repair—processes intimately linked to tumor initiation and progression [9]. Notably, RT significantly affects both the localization and expression of HMGB1. Irradiation promotes HMGB1 relocation from the nucleus to the cytoplasm and modulates cell proliferation and migration through interactions with specific membrane receptors [11]. Moreover, elevated HMGB1 protein expression correlates negatively with prognosis and survival in cancer patients receiving RT [12]. Given its multifaceted roles in radiation responses, HMGB1 has emerged as a potential modulator of radioresistance in various malignancies. However, its specific involvement in cervical cancer radioresistance remains largely unexplored. Additionally, although crosstalk between HMGB1 and metabolic pathways such as AMPK signaling has been suggested, whether this interaction contributes to radioresistance in cervical cancer has not been addressed. AMP-activated protein kinase (AMPK) functions as a heterotrimeric complex comprising one catalytic alpha subunit and two regulatory beta and gamma subunits [13]. AMPK serves as a cellular energy sensor, monitoring intracellular ATP levels. Under conditions of energy deprivation, AMPK activates specific enzymes and phosphorylation cascades to enhance ATP production while reducing ATP consumption, thereby earning its reputation as a guardian of metabolic homeostasis and mitochondrial stability [14]. The AMPK signaling pathway has attracted considerable attention as a potential therapeutic target for various metabolic disorders, including diabetes, obesity, fatty liver disease, and cancer. Previous studies have explored targeting AMPK signaling to overcome drug resistance in cancer therapy [15]. Furthermore, AMPK activation may represent a viable strategy for counteracting radiation resistance [16]. However, the connection between HMGB1 and AMPK signaling in the context of RT resistance remains poorly understood. These considerations led us to investigate whether HMGB1 contributes to radioresistance in cervical cancer through modulation of AMPK/mTOR signaling. In the present study, we established HeLa RT-resistant (HeLa-R) cells and examined the effect of HMGB1 on RT resistance and its underlying molecular pathway. Our findings may provide mechanistic insights and identify potential therapeutic targets for overcoming radioresistance in cervical cancer treatment. Methods and materials Patients and samples collection This retrospective study included CC patients treated with definitive radiotherapy at Taizhou Hospital of Zhejiang Province, categorized as radiosensitive (RS) or radioresistant (RR) based on treatment outcomes. RS cases were defined as those with a recurrence-free interval exceeding six months post-treatment [17], whereas RR cases included patients who either failed to achieve complete clinical response (CR) after initial radiotherapy or experienced in-field relapse within six months of CR [17]. Eligible participants met the following criteria: (1) histologically confirmed squamous cell carcinoma or adenocarcinoma, (2) accessible pretreatment tumor biopsies, (3) no prior radiotherapy or systemic therapy, and (4) International Federation of Gynecology and Obstetrics (FIGO) stage IB2–IIIC according to the FIGO 2018 staging system. Exclusion criteria comprised (1) distant metastasis at diagnosis, (2) a history of other malignancies, (3) tumor specimens with < 70% cellularity, and (4) insufficient follow-up (< 6 months). All patients underwent concurrent chemoradiotherapy. To balance potential confounders (e.g., age, tumor size), propensity score matching was applied, resulting in 22 matched pairs per group for analysis. Pretreatment tumor tissues were collected, flash-frozen in liquid nitrogen, and stored at -80 °C. The study protocol was approved by the Institutional Ethics Committee (Approval number: K20250545), and all participants provided written informed consent. The clinical information of these 44 patients was summarized in (Table 1). Table 1Clinicopathological characteristics of cervical cancer patients with RS or RRRR (N = 22)RS (N = 22) P Age < 5014(63.64%)8(36.36%)0.074 ≥ 508(36.36%)14(63.64%)Family history Yes12(54.55%)10(45.45%)0.551 No10(45.45%)12(54.55%)Post-menopause Yes9(40.91%)16(72.73%)0.035 No13(59.09%)6(27.27%)Histological typeSquamous-cell carcinoma8(36.36%)5(22.73%)0.687Adenocarcinoma8(36.36%)11(50.00%)Adeno-squamous carcinoma6(27.27%)6(27.27%)Tumor size (cm) < 56(27.27%)12(54.55%)0.069 ≥ 516(72.73%)10(45.45%)Differentiation degree Low4(18.18%)12(54.55%)0.002 Medium9(40.91%)9(40.91%) High9(40.91%)1(4.55%)Lymph node metastasis Positive10(45.45%)8(36.36%)0.544 Negative12(54.55%)14(63.64%)FIGO IB25(22.73%)4(18.18%)0.560 II4(18.18%)7(31.82%) III5(22.73%)6(27.27%) IVA8(36.36%)5(22.73%)The data were shown as n (percentage). RS, radiotherapy-sensitivity; RR, radiotherapy-resistant; FIGO, International Federation of Gynecology and Obstetrics Clinicopathological characteristics of cervical cancer patients with RS or RR The data were shown as n (percentage). RS, radiotherapy-sensitivity; RR, radiotherapy-resistant; FIGO, International Federation of Gynecology and Obstetrics Cell culture Human CC cell (HeLa; #CL0134) were obtained from Fenghui Biotech Co. Ltd., (Changsha, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM; #10566016; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; #C0235; Beyotime Biotech Co. Ltd., Shanghai, China) and 1% penicillin/streptomycin (#C0222; Beyotime). The culture temperature and humidified atmosphere was 37℃ and 5% CO2. The medium was replaced every 3–4 days. Establishment and verification of HeLa radiotherapy resistance (HeLa-R) and SiHa radiotherapy resistance (SiHa-R) cells Human CC HeLa and SiHa cells at the logarithmic growth phase were seeded into 10 cm plastic culture dishes at a density of 1 × 10⁶ cells per dish. Each dish was supplemented with 8 mL of complete culture medium, followed by incubation at 37℃ in a 5% CO₂ humidified atmosphere for 24 h. Subsequently, cells were irradiated with X-rays at a dose rate of 2 Gy/min (2 Gy per fraction) using an X-320ix irradiator (Precision X-Ray, Inc., North Branford, CT, USA) at room temperature. Following each irradiation, cells were returned to the incubator and cultured until they reached 60–70% confluence, at which point the next round of irradiation was initiated. A total of 25 consecutive rounds of fractionated irradiation were administered, resulting in a cumulative total dose of 50 Gy [18]. For functional validation of the established radioresistant cells, stably passaged irradiated HeLa and SiHa cells were divided into two groups: control and RT. Cells in the control group were cultured under standard conditions without additional radiation exposure. Cells in the RT group received additional radiation treatment using the identical irradiation protocol as described for resistant cell establishment, except that only 6 consecutive rounds of irradiation were administered, yielding a final cumulative dose of 12 Gy. Finally, methyl thiazolyl tetrazolium (MTT) assay, colony formation assay, Transwell migration assay, and Transwell invasion assay were performed to confirm the successful establishment of HeLa-R and SiHa-R cells. Cell transfection Short hairpin RNA targeting HMGB1 (shHMGB1) and a negative control shRNA (shNC) were procured from Thermo Fisher. A total of 5 × 105 HeLa-R cells were seeded in a 6-well plate (#FCP060; Beyotime). Once the cells reached approximately 80% confluence, transfection was conducted using Lipofectamine 3000 (Thermo Fisher) for 48 h. Subsequently, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was utilized to assess the expression level of HMGB1. shNC: 5′-CCTAAGGTTAAGTCGCCCTCGCTC-3′; shHMGB1: 5′-CACCGCGAAGAAACTGGGAGAGATGTTCAAGAGACATCTCTCCCAGTTTCTTCGCTTTTTTG-3′. Dorsomorphin, GDC-0980 and MHY1485 treatment Dorsomorphin is an inhibitor of AMPK. HeLa-R cells were treated with 40 µM of dorsomorphin (purity, 99.1%; #HY-13418 A; MedChem Express, Monmouth Junction, NJ, USA) to inhibit the AMPK signaling. GDC-0980 is a novel class I phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. HeLa-R cells were treated with 10 µM of GDC-0980 (purity, 99.29%; #HY-13246; MedChem Express) for 24 h. MHY1485 is a mTOR activator, HeLa-R cells were treated with 10 µM MHY1485 (purity, 99.93%; #HY-B0795; MedChem Express, Monmouth Junction, NJ, USA) for 24 h. MTT assay The MTT assay was conducted to evaluate cell viability utilizing a commercial MTT kit (#C0009S; Beyotime) in accordance with the provided instructions. Initially, 25 mg of MTT powder was dissolved in 5 mL of MTT solvent to prepare a 5 mg/mL MTT solution. Subsequently, 2 × 10³ cells per well were seeded into 96-well plates (#FCP962; Beyotime). This seeding density was optimized in preliminary experiments to ensure logarithmic growth throughout the assay period without reaching confluence, which could affect metabolic activity and absorbance readings. Three replicate wells were set up for each experimental condition. After 48 h of treatment (or as indicated for specific experiments), 100 µL of the MTT solution was introduced to each well and incubated with the cells at 37 °C for 4 h. This 4-hour incubation time was selected based on the manufacturer’s recommendations and preliminary time-course experiments (2, 4, and 6 h), which showed that 4 h provided optimal formazan crystal formation with minimal background absorbance and without cytotoxicity. Afterwards, 100 µL of Formazan solution was added to each well, and the mixture was further incubated at 37 °C for 3–4 h until the formazan was fully dissolved. Subsequently, the absorbance was measured at 570 nm using a microplate reader (Thermo Fisher). Colony formation assay To detect colony formation, cells were seeded in 6-well plates at a density of 1 × 103 cells per well and incubated at 37 °C for two weeks. Subsequently, the cells were fixed using 1 mL of 4% paraformaldehyde (#P0099; Beyotime) at 4 °C for one hour. After fixation, the cells were washed once with phosphate buffer solution (PBS; #C0221A; Beyotime) and stained with 1000 µL of crystal violet (#C0121; Beyotime) for 2 min. Finally, the stained cells were rinsed with double distilled water and counted using a microscope (Olympus, Tokyo, Japan). Transwell migration and invasion assays The Transwell migration and invasion assays were conducted following the published protocols [19]. For the migration assay, 4 × 104 HeLa-R cells were placed in serum-free medium within the upper chamber of a Transwell insert (8-mm pore size; Corning Inc., NY, USA), while the lower chamber was filled with a medium containing 10% FBS to serve as a chemoattractant. In the invasion assay, the upper chamber was coated with Matrigel (BD Bioscience, San Jose, CA, USA) and populated with 9 × 104 cells, with the lower chamber also containing a medium with 10% FBS. After an incubation period of 48 h at 37 °C in a 5% CO2 atmosphere, the Transwell chamber was removed, and the medium in the well was discarded and rinsed with calcium-free PBS. The cells were subsequently fixed in methanol (#322415; Sigma-Aldrich, St. Louis, MO, USA) for 30 min and stained with 0.1% crystal violet for 20 min. The cells that had not migrated were carefully removed using a cotton swab and counted using a microscope (Thermo Fisher). qRT-PCR Total RNA was extracted from the cells utilizing the commercial MolPure® TRIeasy™ plus total RNA kit (#19211ES; Yeason Biotech Co. Ltd., Shanghai, China). Subsequently, the RNA underwent reverse transcription to cDNA using the Hifair® Ⅲ Reverse Transcriptase (#14601ES; Yeason) Next, the PCR amplification was conducted using Hieff® qPCR SYBR Green Master Mix (#11201ES; Yeason), adhering to the following reaction conditions: 95 °C for 5 min, 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and a melt curve stage. The primers employed in this research were synthesized by Thermo Fisher and are detailed as follows: high mobility group box-1 protein (HMGB1), forward, 5′-TATGGCAAAAGCGGACAAGG-3′ and reverse, 5′-CTTCGCAACATCACCAATGGA-3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5′-TGTGGGCATCAATGGATTTGG-3′ and reverse, 5′-ACACCATGTATTCCGGGTCAAT-3′. GAPDH is considered an internal reference gene and the gene expression levels were determined using the 2−ΔΔCT method. Western blot The total protein extraction kit for cells (#PK10020; Proteintech Biotech Co. Ltd., Wuhan, China) was utilized to extract proteins from the cells following the provided protocol. Subsequently, the homogenate was processed, and the supernatant was collected and preserved at -80℃ for future use. The Bradford protein assay kit (#P0006; Beyotime) was then employed to measure the protein concentration. Following this, 30 µg of protein was subjected to separation via 10% SDS-PAGE and subsequently transferred to a polyvinylidene fluoride (PVDF) membrane (#FFP39; Beyotime). The membrane was blocked using a commercial blocking solution (#P0242; Beyotime) for 10 min and incubated overnight at 4 °C with primary antibodies [HMGB1 (#ab227168, 1/2000; Abcam), AMPK (#ab271188, 1/1000; Abcam), p-AMPK (#ab133448, 1/1000; Abcam), silent information regulator 1 (SIRT1; #ab189494, 1/1000; Abcam), p-mTOR (#ab109268, 1/5000; Abcam), mTOR (#ab134903, 1/10,000; Abcam), p-acetyl coenzyme A carboxylase (ACC; #3661, 1/1000; Cell Signaling Technology, Danvers, MA, USA), ACC (#ab109368, 1/5000; Abcam), forkhead box O3 (FOXO3; #ab109629, 1/5000; Abcam), p-p53 (#ab33889, 1/5000; Abcam), p53 (#ab32049, 1/5000; Abcam), β-actin (#ab8227, 1/5000; Abcam)]. Following this, the membrane was treated with the secondary antibody (#ab6721, 1/10,000; Abcam) for 1 h at room temperature. Finally, protein signal detection was conducted using an enhanced chemiluminescence solution (Sigma), and the specific proteins were visualized with the Odyssey™ Infrared Imaging System (Gene Company Limited, Hong Kong, China). Immunofluorescence (IF) IF staining was conducted to assess the expression of HMGB1 in HeLa and HeLa-R cells. The cells cultured on glass slides were washed three times with PBS and subsequently fixed in 4% paraformaldehyde for 30 min. Following fixation, the sections were rinsed three times with PBS, permeabilized using 0.1% Triton-X100 (#P0096B; Beyotime) for 20 min at room temperature, and then blocked with an immunostaining blocking buffer (#P0102; Beyotime). The cells were incubated overnight at 4°C with an HMGB1 antibody (#ab79823; 1/250; Abcam). After washing, the slides were treated with a goat anti-rabbit secondary antibody (#ab150077; 1/500; Abcam) for one hour at room temperature. The samples were then stained with 4’,6’-diamidino-2-phenylindole (DAPI) staining solution (#C1005; Beyotime). Representative images were captured using a confocal microscope (Thermo Fisher). Phospho-kinase array Phospho-kinase array was performed to detect the relative levels of phosphorylation of kinase phosphorylation sites. Human Phospho-Kinase Array kit (#ARY003B) was purchased from R&D Systems (USA), and the assays were performed referring to a previous study [20]. Briefly, 1 × 107 cells were solubilized in the lysis buffer and rocked gently at 4℃ for 30 min. After centrifugation at 14,000 g for 5 min, the whole protein concentration in the supernatants was quantified. Afterward, the cell lysates were mixed with a cocktail of biotinylated detection antibodies and incubated overnight with membranes captured with “capture” and control antibodies. After that, the membranes were washed, and streptavidin-horseradish peroxidase and chemiluminescent detection reagents were applied. A signal was produced at each capture spot corresponding to the amount of a phosphorylated protein bound. Flow cytometry HeLa-R cells were harvested by trypsinization and washed twice with ice-cold phosphate-buffered saline (PBS). The cells were then resuspended in 1× binding buffer at a concentration of 1 × 10⁶ cells/mL. For the discrimination of apoptotic and viable cells, 100 µL of the cell suspension was incubated with 5 µL of 7-aminoactinomycin D (7-AAD; #00-6993-50; Thermo Fisher Scientific, Waltham, MA, USA) for 15 min at room temperature in the dark. After incubation, 400 µL of 1× binding buffer was added to each tube, and the samples were immediately analyzed and sorted using a BD FACSAria™ III cell sorter (BD Biosciences, San Jose, CA, USA). The sorting gate was established based on the fluorescence intensity of 7-AAD (FL3 channel). Two distinct populations were identified: Population A (7-AAD-high), representing apoptotic cells, and Population B (7-AAD-low/negative), representing viable cells. Sorting was performed at a flow rate of 1,000–2,000 events per second using a 100-µm nozzle. Sorted cells were collected into sterile tubes containing complete culture medium and subsequently processed for protein extraction and Western blot analysis. Purity checks were performed post-sort to confirm sorting efficiency (> 95%). Statistical analysis Data are expressed as mean±standard deviation (SD) from at least three independent experiments (n = 3 per group). For in vitro studies, comparisons between two groups were analyzed using unpaired two-tailed Student’s t-tests, while multiple groups were compared via one-way ANOVA with Tukey’s post hoc correction. For clinical data, categorical variables (e.g., menopausal status, differentiation degree) were assessed using the Chi-square test, and continuous variables (e.g., age) were compared via independent t-tests. Statistical significance was set at p < 0.05. All analyses were performed using SPSS 21.0 (IBM, USA) and visualized with GraphPad Prism 8.0.1 (GraphPad Software, USA). Results Successful establishment of HeLa-R cells In this study, we treated the HeLa cells with X-ray irradiation. To verify the successful establishment of HeLa-R, we treated the irradiated HeLa cells with or without RT. The results showed that there were no significant differences in cell viability, the number of cloned, migrated cells, invaded cells and apoptosis rate between the control and RT groups (Figs. 1A-E). These results indicated that we have successfully established the HeLa-R cells. Successful establishment of HeLa-R cells. A, Cell viability in the control and RT group was detected by MTT assay; B, Colony formation assay was performed to analyze the cell proliferation between the control and RT groups; Transwell C, migration and D, invasion assays were used to assess the cell migration and invasion between the control and RT groups; E, Flow cytometry was performed to detect the apoptosis rate between the control and RT groups. Data are mean ± SD (n = 3 independent experiments). Comparisons were made by unpaired t-test (ns: not significant). MTT, methyl thiazolyl tetrazolium; RT, radiotherapy RT resistance in HeLa cells might be due to the increased expression of HMGB1 HMGB1, a nuclear protein released during RT, has a location-dependent function and regulates the proliferation and migration of tumor cells by binding to high-affinity receptors [21]. In the present study, we aimed to discuss the role of HMGB1 in RT in HeLa cells. QRT-PCR and Western blot results demonstrated that resistant HeLa cells showed higher HMGB1 mRNA and protein levels compared with the parental HeLa cells (Figs. 2A and B). Besides, IF results displayed the increased expression of HMGB1 in resistant HeLa cells in contrast to the parental HeLa cells (Fig. 2C). These results suggested that RT resistance in HeLa cells might be due to the increased expression of HMGB1. Notably, HMGB1 upregulation in HeLa-R cells was sustained even after discontinuation of radiation exposure, as all functional assays were performed on cells maintained in culture without further irradiation. This indicates that elevated HMGB1 expression is part of a stable, acquired radioresistant phenotype rather than a transient stress response. RT resistance in HeLa cells might be due to the increased expression of HMGB1. The mRNA and protein levels of HMGB1 in parental and resistant groups were detected by A, qRT-PCR and B, Western blot; C, IF staining was performed to evaluate the expression of HMGB1 in parental and resistant groups. In parental HeLa cells, D, Cell viability in the control and RT group was detected by MTT assay; E, Colony formation assay was performed to analyze the cell proliferation between the control and RT groups; Transwell F, migration and G, invasion assays were used to assess the cell migration and invasion between the control and RT groups; H, Flow cytometry was performed to detect the apoptosis rate between the control and RT groups. Data are mean ± SD (n = 3 independent experiments). Comparisons were made by unpaired t-test (**p<0.01, ***p<0.001). HMGB1, high mobility group box-1 protein; qRT-PCR, reverse transcription-polymerase chain reaction; IF, immunofluorescence; MTT, methyl thiazolyl tetrazolium Furthermore, In parental HeLa cells, RT treatment significantly decreased the cell viability (Fig. 2D), cloned cells (Fig. 2E), migrated cells (Fig. 2F), invaded cells (Fig. 2G), and increased the apoptosis rate (Fig. 2H). However, in HMGB1 overexpressed HeLa cells, RT treatment showed no effects on the cell viability, cloned cells, migrated cells, invaded cells and apoptosis rate (Supplementary Fig. 1). HMGB1 deficiency inhibited the RT resistance of HeLa-R cells In order to further investigate the function of HMGB1 in HeLa-R cells, we conducted cell transfection using shNC and shHMGB1 vectors. The findings indicated that following the inhibition of HMGB1, there was a reduction in the mRNA and protein levels of HMGB1 within the HeLa-R cells (Fig. 3A-B). Furthermore, compared with the shNC group, shHMGB1 group showed decreased cell viability, number of cloned, migrated and invaded cells, and increased apoptosis rate (Figs. 3C-H). These outcomes suggested that HMGB1 deficiency inhibited the RT resistance of HeLa-R cells. Phospho-kinase array results showed that HMGB1 knockdown did not affect most of the kinases on the chip, but specifically upregulated the phosphorylation of AMPK (Fig. 3I). Thus, we detected the protein level of pAMPK/AMPK. The results showed that HMGB1 inhibition increased the protein level of pAMPK/AMPK in HeLa-R cells (Fig. 3J). Furthermore, we further explore the role of HMGB1 overexpression in HeLa-R cells. The results showed that HMGB1 overexpression significantly increased the cell viability, the number of cloned, migrated and invaded cells, decreased apoptosis rate and pAMPK protein levels in HeLa-R cells (Supplementary Fig. 2). HMGB1 deficiency inhibited the RT resistance of HeLa-R cells. A-B, QRT-PCR and Western blot was used to detect the expression of HMGB1 after HMGB1 inhibition in HeLa-R cells; C, MTT assay was performed to assess the cell viability in the shNC and shHMGB1 groups; D, Colony formation assay was performed to analyze the cell proliferation in the shNC and shHMGB1 groups; Transwell E, migration and F, invasion assays were used to assess the cell migration and invasion in the shNC and shHMGB1 groups. G-H, Flow cytometry was performed to detect the apoptosis rate in the shNC and shHMGB1 groups. I, Human phospho-kinase array was performed to analyze the differential phospho-proteins between shNC- and shHMGB1-transfetced HeLa-R cells. J, Western blot analysis of pAMPK and AMPK protein levels in shNC and shHMGB1 groups in HeLa-R cells. Data are mean ± SD (n = 3 independent experiments). Comparisons were made by unpaired t-test (**p<0.01, ***p<0.001). qRT-PCR, reverse transcription-polymerase chain reaction; HMGB1, high mobility group box-1 protein; MTT, methyl thiazolyl tetrazolium; shRNA, short hairpin RNA; HeLa-R, HeLa radiotherapy resistance. AMPK, AMP-activated protein kinase In addition, we also used the SiHa cell to further confirm the conserved role of HMGB1 in regulating radioresistance. SiHa-R cells were established using the same fractionated X-ray irradiation protocol as HeLa-R cells. To verify the successful establishment of SiHa-R, the irradiated SiHa cells were treated with or without additional RT. The results showed that there were no significant differences in cell viability, the number of cloned, migrated, invaded cells, and apoptosis rate between the control and RT groups (Supplementary Fig. 3). These results indicated that we have successfully established the SiHa-R cells. Then, in SiHa-R cells, HMGB1 knockdown significantly decreased the cell viability, migration and invasion abilities, increased the apoptosis rate and the protein level of pAMPK/AMPK of SiHa-R cells (Supplementary Fig. 4). These results implied that HMGB1 might play a role in HeLa and SiHa-R cell RT resistance via regulating AMPK signaling. HMGB1 inhibition suppressed RT resistant in HeLa-R cells through activating the AMPK and mTOR signaling In order to screen the downstream targets of AMPK, Western blot was used to detect the protein expressions of some potential AMPK substrates, including SIRT1, mTOR, ACC, FOXO3 and p53. The results showed that HMGB1 knockdown increased the pAMPK protein levels and decreased the pmTOR protein levels in HeLa-R cell RT resistance, while the protein levels of SIRT1, ACC, FOXO3 and p53 showed no significant differences. Then the shHMGB1 transfected HeLa-R cells were treated with dorsomorphin (AMPK inhibitor), GDC-0980 (mTOR inhibitor), and MHY1485 (mTOR activator). The treatment of dorsomorphin, GDC-0980, and MHY1485 reversed the regulatory effects of shHMGB1 on pAMPK and pmTOR (Fig. 4A). In addition, The treatment of dorsomorphin, GDC-0980, and MHY1485 increased the cell viability, number of cloned, migrated and invaded cells, and decreased apoptosis rate of shHMGB1 transfected HeLa-R cells (Fig. 4B-F). The results suggested that HMGB1 inhibition suppressed RT resistant in HeLa-R cells through activating the AMPK signaling, then inhibiting mTOR signaling. HMGB1 inhibition suppressed RT resistant in HeLa-R cells through activating the AMPK and mTOR signaling. HeLa-R cells were transfected with shHMGB1 and treated with dorsomorphin (AMPK inhibitor), GDC-0980 (a dual PI3K/mTOR inhibitor), and MHY1485 (mTOR activator). A, Western blot was performed to detect the Western blot was performed to detect the protein levels of SIRT1, p-mTOR, mTOR, p-ACC, ACC, FOXO3, p-p53, and p53 in each group in HeLa-R cells; B, MTT assay was performed to assess the cell viability in each group in HeLa-R cells; C, Colony formation assay was performed to analyze the cell proliferation in each group in HeLa-R cells; Transwell D, migration and E, invasion assays were used to assess the cell migration and invasion in each group in HeLa-R cells. F, Flow cytometry was performed to detect the apoptosis rate in each group in HeLa-R cells. Data represent mean ± SD (n = 3). Comparisons were made by one-way ANOVA with Tukey’s test (*p<0.05, ***p<0.001). qRT-PCR, reverse transcription-polymerase chain reaction; HMGB1, high mobility group box-1 protein; MTT, methyl thiazolyl tetrazolium; shRNA, short hairpin RNA; HeLa-R, HeLa radiotherapy resistance. AMPK, AMP-activated protein kinase. mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; SIRT1, silent information regulator 1; ACC, acetyl coenzyme A carboxylase; FOXO3, Forkhead Box O3; p53, protein 53 Population B cells showed elevated protein levels HMGB1 and p-mTOR/mTOR and reduced that of p-AMPK/AMPK Flow cytometry was employed to distinguish apoptotic (Population A) and viable (Population B) subpopulations in HeLa-R cells (Fig. 5A). Western blot analysis revealed that Population B cells displayed elevated HMGB1 and p-mTOR/mTOR protein levels but reduced p-AMPK/AMPK ratios relative to Population A. Furthermore, the protein levels of SIRT1, p-ACC/ACC, FOXO3, and p-p53/p53 between two groups showed no significant differences (Fig. 5B). Population B cells showed elevated protein levels HMGB1 and p-mTOR/mTOR and reduced that of p-AMPK/AMPK. A, Flow cytometry was employed to distinguish apoptotic (Population A) and viable (Population B) subpopulations in HeLa-R cells; B, Western blot was performed to detect the protein levels of HMGB1, p-AMPK/AMPK, SIRT1, p-mTOR/mTOR, p-ACC/ACC, FOXO3, and p-p53/p53 in HeLa-R cells. (n = 3 independent experiments). HeLa-R, HeLa radiotherapy resistance; HMGB1, high mobility group box-1 protein; mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; SIRT1, silent information regulator 1; ACC, acetyl coenzyme A carboxylase; FOXO3, Forkhead Box O3; p53, protein 53.shRNA, short hairpin RNA Clinicopathological characteristics of CC patients with RS or RR The clinicopathological characteristics of CC patients were analyzed to evaluate their association with RS or RR. The results are summarized in Table 1. No significant differences were observed between the two groups in age, family history, histological type, tumor size, lymph node metastasis, or FIGO stage (all p > 0.05). However, menopausal status was significantly correlated with radiotherapy response (p = 0.035). In the RR group, 9 patients (40.91%) were post-menopausal, while 13 (59.09%) were non-postmenopausal. In contrast, the RS group included 16 post-menopausal patients (72.73%) and 6 non-postmenopausal patients (27.27%). Additionally, tumor differentiation degree was significantly associated with radiotherapy response (p = 0.002). In the RR group, 4 patients (18.18%) exhibited low differentiation, 9 (40.91%) had moderate differentiation, and 9 (40.91%) showed high differentiation. Conversely, in the RS group, 12 patients (54.55%) had low differentiation, 9 (40.91%) had moderate differentiation, and only 1 (4.55%) displayed high differentiation. The protein level of HMGB1 was elevated in the CC tissues of RS patients, while the levels of pAMPK/AMPK were decreased Subsequently, we enrolled CC patients with RS or RR and collected their CC tissues for clinical verification. Results showed that compared with the CC tissues with RS patients, the HMGB1 mRNA level was increased in the tumor tissues of CC patients with RR (Fig. 6A). In addition, Western blot results showed that the protein level of HMGB1 was upregulated, while that of p-AMPK was downregulated in the tumor tissues of CC patients with RR in comparison to the CC patients with RS (Fig. 6B). The protein level of HMGB1 was elevated in the CC tissues of RS patients, while the levels of pAMPK/AMPK were decreased. A, The HMGB1 mRNA level in CC tissues of patients in the RS group and the RR group was detected by qRT-PCR; B, The protein levels of HMGB1, p-AMPK, AMPK in CC tissues of patients in the RS group and the RR group were analyzed by Western blot. Data are mean ± SD (n = 22 independent experiments). Comparisons were made by unpaired t-test (**p<0.01). HMGB1, high mobility group box-1 protein; AMPK, AMP-activated protein kinase; CC, cervical cancer; RS, radiosensitive; RR, radioresistant; qRT-PCR, reverse transcription-polymerase chain reaction Discussion CC is a gynecological malignancy linked to HPV, with RT being the primary treatment option. Nevertheless, the presence of resistance to RT has resulted in suboptimal therapeutic outcomes, posing a significant public health challenge in China. In the present study, we successfully established the HeLa-R cells. HMGB1 serves as a crucial element in both physiological and pathological processes, including the modification of DNA structure and the regulation of transcription [22]. Overexpression of HMGB1 can inhibit apoptosis of tumor cells and induce cell differentiation, cell migration, and cell proliferation [23]. Recent studies have proved that HMGB1 plays an important role in tumor RT resistance, and its regulatory mechanism needs to be further clarified. In our research, we observed an elevation in HMGB1 expression within HeLa-R cells. This finding aligns with existing literature indicating that HMGB1 is abundantly expressed in various tumors, including colorectal, pancreatic, and liver cancers, and is closely associated with patient prognosis [24–27]. Furthermore, the absence of HMGB1 was found to reduce the viability, migration, and invasion of HeLa-R cells. Previous studies have similarly indicated that the downregulation of HMGB1 increases the sensitivity of multiple tumor cell types to radiotherapy, such as breast cancer, esophageal squamous cell carcinoma, and bladder cancer [28–30]. Additionally, the silencing of HMGB1 has been shown to diminish the proliferation and invasive capabilities of non-small cell lung cancer cells while enhancing their radiosensitivity [31]. Moreover, Chen et al. have suggested that the inhibition of HMGB1 leads to a reduction in the migration of damaged cells following radiation exposure, thereby preventing the recurrence and metastasis of pancreatic cancer [32]. AMPK is an energy sensor with aberrant expression in various diseases [33]. The involvement of the AMPK signaling pathway in tumor progression has been extensively reported. In our research, we observed that the inhibition of HMGB1 led to an increase in the protein levels of pAMPK in HeLa-R cells. Furthermore, HMGB1 inhibition reduced cell viability, as well as the number of clones, migrated, and invaded cells in HeLa-R cells. This indicates that HMGB1 inhibition mitigates radioresistance in HeLa-R cells by activating the AMPK signaling pathway. The molecular mechanism by which HMGB1 regulates AMPK/mTOR signaling likely involves both intracellular and extracellular pathways. Upon radiation-induced stress, HMGB1 can translocate to the cytoplasm and be released into the extracellular milieu, where it binds to receptors such as RAGE and TLR4. Activation of RAGE has been shown to modulate AMPK activity through regulation of cellular redox status and mitochondrial function, while TLR4 signaling can influence energy homeostasis via NF-κB-dependent mechanisms [34]. Additionally, HMGB1 may indirectly impact AMPK by altering autophagic flux, as AMPK is a central regulator of autophagy [35]. Future studies should investigate whether HMGB1 directly interacts with upstream kinases of AMPK or affects AMPK subunit composition in cervical cancer cells. Previous studies have similarly demonstrated that the activation of the AMPK signaling pathway enhances the sensitivity of cancer cells to radiation therapy [15, 36]. In addition, inhibition of AMPK promotes resistance and recurrence of another method of treatment for tumors, chemotherapy [37]. Interestingly, AMPK activation has the potential to alleviate adverse effects associated with radiation therapy, including dysfunction of the salivary glands [38]. Notably, Jin et al. reveal that the AMPK pathway is significantly activated in patients with colorectal cancer who exhibit radioresistance. This finding contrasts with our results, which may be attributed to variations in the types of cancer studied [16]. In our subsequent study, mTOR was identified as an downstream target of AMPK signaling in HeLa-R cells. Similarly, Lin et al. [39] demonstrated that long non-coding RNA (lncRNA) CASC19 contributes to radioresistance of nasopharyngeal carcinoma via regulating AMPK/mTOR pathway. Additionally, a previous study discovers that elevated 3-phosphoinositide-dependent protein kinase 1 (PDK1) expression drives PI3K/protein kinase B (AKT)/mTOR signaling promotes radiation-resistant in hepatocellular carcinoma [40]. In our clinical research, we found that menopausal status and differentiation degree were significantly correlated with radiotherapy response. Song et al. [41] also revealed that menopause status was significantly correlated with the response to radiotherapy. However, there was no significant difference between differentiation degree and radiotherapy response. The reason for such a difference might lie in the inherent differences among the selected group of people. Similarly, previous research have also discovered that age, FIGO stage, tumor histology, tumor size were not correlated with the response to radiotherapy in CC [42, 43]. In addition, our clinical data revealed a positive correlation between HMGB1 expression and tumor differentiation degree in cervical cancer. The RR group exhibited higher HMGB1 levels and predominantly well-differentiated tumors, whereas the RS group showed lower HMGB1 expression and predominantly poorly differentiated tumors. This suggests that HMGB1 may be associated with maintaining a more differentiated phenotype in cervical cancer cells, potentially contributing to radioresistance through mechanisms involving the AMPK/mTOR pathway. These findings align with HMGB1’s known roles in chromatin remodeling and transcriptional regulation [44, 45], although further studies are needed to elucidate the direct molecular links between HMGB1 and differentiation-related genes. We attempted to validate the prognostic significance of HMGB1 using TCGA cervical cancer dataset; however, no statistically significant association with patient survival was observed at the mRNA level. This may reflect the importance of post-transcriptional regulation and protein-level functional status of HMGB1, including its nuclear-cytoplasmic translocation and extracellular release, which cannot be captured by mRNA expression data alone. Importantly, multiple immunohistochemistry-based studies have consistently demonstrated that HMGB1 protein overexpression correlates with poor prognosis in cervical cancer patients [46–48], supporting the clinical relevance of our findings. In our clinical analysis, we observed an association between HMGB1 expression, p-AMPK levels, and radiotherapy response in cervical cancer patients. Specifically, tumor tissues from radiosensitive patients showed lower HMGB1 expression and higher p-AMPK levels compared to radioresistant patients. However, as these findings are correlational, they do not establish a causal relationship between HMGB1/AMPK signaling and clinical radiotherapy outcomes. In conclusion, this research demonstrates that, in cellular models of cervical cancer radioresistance, HMGB1 enhances radioresistance in HeLa cells by modulating the AMPK/mTOR signaling pathway. Furthermore, clinical data reveal significant correlations between HMGB1/p-AMPK levels and radiotherapy response. However, due to the lack of direct validation of p-mTOR/mTOR expression in patient tissues, the complete pathway in a clinical setting remains to be established. Future prospective studies with larger cohorts are needed to confirm the clinical utility of targeting the HMGB1/AMPK/mTOR axis. This investigation serves as a valuable reference for identifying potential therapeutic targets for CC treatment. This study has several limitations. First, our mechanistic conclusions were only validated in in vitro cell models without in vivo verification. Due to time and resource constraints, we were unable to complete animal experiments in this work. Future studies will construct subcutaneous xenograft, lung metastasis, and patient-derived organoid models to systematically evaluate the in vivo efficacy, anti-metastatic activity, and safety of combining HMGB1/AMPK/mTOR targeting with radiotherapy, as well as its synergy with conventional chemoradiotherapy. Notably, the lack of p-mTOR/mTOR data in clinical samples prevents definitive confirmation of the complete HMGB1/AMPK/mTOR axis in patient tumors, and our mechanistic model is currently supported solely by in vitro gain- and loss-of-function experiments. Second, insufficient residual clinical tissue precluded analysis of p-mTOR/mTOR expression and its correlation with HMGB1 and p-AMPK. We will expand the clinical cohort and conduct prospective studies to further assess the value of this pathway as a predictive biomarker and therapeutic target for cervical cancer radiotherapy. Finally, the use of the dual PI3K/mTOR inhibitor GDC-0980 did not allow dissection of the individual contributions of mTOR and PI3K to the observed effects, and future validation using selective mTOR inhibitors (e.g., rapamycin) is warranted. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Figure 1: HMGB1 overexpression counteracted the role of RT in parental HeLa cells. The mRNA and protein levels of HMGB1 in HeLa cells were detected by A, qRT-PCR and B, Western blot; In HMGB1 ovreexpression HeLa cells, C, Cell viability in the control and RT group was detected by MTT assay; D, Colony formation assay was performed to analyze the cell proliferation between the control and RT groups; Transwell E, migration and F, invasion assays were used to assess the cell migration and invasion between the control and RT groups; G, Flow cytometry was performed to detect the apoptosis rate between the control and RT groups. Data are mean±SD (n=3 independent experiments). Comparisons were made by unpaired t-test (***p<0.001, ns: not significant).HMGB1, high mobility group box-1 protein; MTT, methyl thiazolyl tetrazolium; RT, radiotherapy. Supplementary Figure 2: HMGB1 overexpression promoted the malicious behaviors of HeLa-R cells. A-B, QRT-PCR and Western blot was used to detect the expression of HMGB1 after HMGB1 overexpression in HeLa-R cells; C, MTT assay was performed to assess the cell viability in the vector and HMGB1 groups; D, Colony formation assay was performed to analyze the cell proliferation in the vector and HMGB1 groups; Transwell E, migration and F, invasion assays were used to assess the cell migration and invasion in the vector and HMGB1 groups. G, Flow cytometry was performed to detect the apoptosis rate in the vector and HMGB1 groups. H, Western blot analysis of pAMPK and AMPK protein levels in vector and HMGB1 groups in HeLa-R cells. Data are mean±SD (n=3 independent experiments). Comparisons were made by unpaired t-test (**p<0.01, ***p<0.001).qRT-PCR, reverse transcription-polymerase chain reaction; HMGB1, high mobility group box-1 protein; MTT, methyl thiazolyl tetrazolium; shRNA, short hairpin RNA; HeLa-R, HeLa radiotherapy resistance. AMPK, AMP-activated protein kinase. Supplementary Figure 3: Successful establishment of SiHa-R cells. A, Cell viability in the control and RT group was detected by MTT assay; B, Colony formation assay was performed to analyze the cell proliferation between the control and RT groups; Transwell C, migration and D, invasion assays were used to assess the cell migration and invasion between the control and RT groups; E, Flow cytometry was performed to detect the apoptosis rate between the control and RT groups. Data are mean±SD (n=3 independent experiments). Comparisons were made by unpaired t-test (ns: not significant).MTT, methyl thiazolyl tetrazolium; RT, radiotherapy. Supplementary Figure 4: HMGB1 deficiency inhibited the RT resistance of SiHa-R cells. A-B, QRT-PCR and Western blot was used to detect the expression of HMGB1 after HMGB1 inhibition in SiHa-R cells; C, MTT assay was performed to assess the cell viability in the shNC and shHMGB1 Acknowledgements Not applicable. Authors’ contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by M W, Y L and B W. The first draft of the manuscript was written by Y X and C Y and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Taizhou Hospital of Zhejiang Province (Approval number: K20250545). Informed consent was obtained from all individual participants included in the study. This study was performed in line with the principles of the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Youyou Xie and Changhui Yu contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Figure 1: HMGB1 overexpression counteracted the role of RT in parental HeLa cells. The mRNA and protein levels of HMGB1 in HeLa cells were detected by A, qRT-PCR and B, Western blot; In HMGB1 ovreexpression HeLa cells, C, Cell viability in the control and RT group was detected by MTT assay; D, Colony formation assay was performed to analyze the cell proliferation between the control and RT groups; Transwell E, migration and F, invasion assays were used to assess the cell migration and invasion between the control and RT groups; G, Flow cytometry was performed to detect the apoptosis rate between the control and RT groups. Data are mean±SD (n=3 independent experiments). Comparisons were made by unpaired t-test (***p<0.001, ns: not significant).HMGB1, high mobility group box-1 protein; MTT, methyl thiazolyl tetrazolium; RT, radiotherapy. Supplementary Figure 2: HMGB1 overexpression promoted the malicious behaviors of HeLa-R cells. A-B, QRT-PCR and Western blot was used to detect the expression of HMGB1 after HMGB1 overexpression in HeLa-R cells; C, MTT assay was performed to assess the cell viability in the vector and HMGB1 groups; D, Colony formation assay was performed to analyze the cell proliferation in the vector and HMGB1 groups; Transwell E, migration and F, invasion assays were used to assess the cell migration and invasion in the vector and HMGB1 groups. G, Flow cytometry was performed to detect the apoptosis rate in the vector and HMGB1 groups. H, Western blot analysis of pAMPK and AMPK protein levels in vector and HMGB1 groups in HeLa-R cells. Data are mean±SD (n=3 independent experiments). Comparisons were made by unpaired t-test (**p<0.01, ***p<0.001).qRT-PCR, reverse transcription-polymerase chain reaction; HMGB1, high mobility group box-1 protein; MTT, methyl thiazolyl tetrazolium; shRNA, short hairpin RNA; HeLa-R, HeLa radiotherapy resistance. AMPK, AMP-activated protein kinase. Supplementary Figure 3: Successful establishment of SiHa-R cells. A, Cell viability in the control and RT group was detected by MTT assay; B, Colony formation assay was performed to analyze the cell proliferation between the control and RT groups; Transwell C, migration and D, invasion assays were used to assess the cell migration and invasion between the control and RT groups; E, Flow cytometry was performed to detect the apoptosis rate between the control and RT groups. Data are mean±SD (n=3 independent experiments). Comparisons were made by unpaired t-test (ns: not significant).MTT, methyl thiazolyl tetrazolium; RT, radiotherapy. Supplementary Figure 4: HMGB1 deficiency inhibited the RT resistance of SiHa-R cells. A-B, QRT-PCR and Western blot was used to detect the expression of HMGB1 after HMGB1 inhibition in SiHa-R cells; C, MTT assay was performed to assess the cell viability in the shNC and shHMGB1 Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.